Announcements

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) executive Patil Neena M sold 1,200 shares at $240.94 per share on 10 September 2026, leaving her with 47,671 shares. The transaction represented about 2.5% of her prior shares holding.

LivaNova PLC (NASDAQ: LIVN) director Francesco Bianchi sold 3,500 shares at $78.01 per share on 10 September 2026. The transaction leaves Bianchi with a stated holding of 4,434 LivaNova shares.

NYMOX PHARMACEUTICAL CORP (OTC: NYMXF) recorded a net loss of $4.275475 million for the year ended December 31, 2025, equal to $0.05 per basic and diluted share. The 2025 loss was $4.275475 million compared with $4.491797 million in 2024, while the per-share result was …

FDA Package Sets Out PH-762 Phase 2b Plan

Quince Therapeutics, Inc. (NASDAQ: QNCX) completed the sale of Quince SpA, related AIDE intellectual property and associated systems to Ayma for $450,000. The transaction covers assets connected with the company’s encapsulated dexamethasone sodium phosphate product candidate for Ataxia-Telangiectasia.

Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) recorded an insider award of 16,250 derivative securities to RA Capital Management, L.P. The transaction left RA Capital Management holding 100.0% of its resulting derivative securities position in Artiva.

Benitec Biopharma Inc. (NASDAQ: BNTC) had $180.0 million in cash and cash equivalents at June 30, 2026, while its BB-301 program progressed through clinical follow-up, enrollment and regulatory planning.